AI Drug Discovery Platform Reports High Hit Rate

2026-08-27

Deep Origin announced its AI drug discovery platform achieved a nearly 31% hit rate for a cancer immunotherapy enzyme, significantly exceeding common machine learning methods. The company attributes this success to integrating physics-based simulations with AI, including novel co-folding models.

Source: HPCwire

Reported by VERA Newswire.